RGEN Repligen Corporation

163.81USD-3.81%Mkt Cap: 10.47B USDP/E: —

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fib…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap10.47B USD
Enterprise Value10.71B USD
Revenue (TTM)805.61M USD
Gross Profit386.25M USD
Net Income (TTM)48.89M USD
Revenue/Share14.28 USD
Last Price163.81 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.0K
CountryUS
SectorHealthcare
IndustryMedical Instruments & Supplies
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)61.77
PEG1.67
EV/EBITDA74.67
EV/Revenue13.30
P/S13.00
P/B4.44
EPS (TTM)-0.21 USD
EPS (Forward)2.65 USD
52W Range
100.9964% of range198.86
52W High198.86 USD
52W Low100.99 USD
Profitability
Gross Margin52.32%
Oper. Margin8.14%
EBITDA Margin17.81%
Profit Margin6.62%
ROE2.32%
ROA1.66%
ROIC1.61%
ROCE1.48%
Growth
Revenue Growth10.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF117.42M USD
CapEx (TTM)25.73M USD
FCF Margin13.85%
FCF Yield1.07%
Net Debt-170.74M USD
Net Debt/EBITDA-1.19
Net Debt/FCF-1.53
Balance Sheet
Debt/Equity0.33
Current Ratio9.88
Quick Ratio8.07
Book Value/Sh36.90 USD
Cash/Share13.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)203.21 USD
Upside (mean)+24.1%
Target Range175.00 USD – 235.00 USD
175.00+24.1% to mean235.00
# Analysts19
Ownership
Shares Out.63.92M
Float60.96M
Insiders4.87%
Institutions114.16%
Short Interest
Short Ratio4.9d
Short % Float11.06%
Short % Out.11.04%
Shares Short7.05M
Short (prev mo.)7.58M
Technical
SMA 50177.08 (-7.5%)
SMA 200145.50 (+12.6%)
Beta1.12
S&P 52W Chg12.00%
Avg Vol (30d)1.16M
Avg Vol (10d)913.57K
Technical Indicators
RSI (14)47.6
MACD-2.5118
MACD Signal-1.8000
MACD Hist.-0.7118
BB Upper187.54 USD
BB Middle174.12 USD
BB Lower160.69 USD
BB Width15.42%
ATR (14)8.302 USD
Vol Ratio (20d)0.70x

About Repligen (NASDAQ: RGEN)

›

Repligen (NASDAQ: RGEN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 2,000 employees.

The shares were at 163.81 USD on 20 November 2026, up 13.0% over 52 weeks. Its 52-week range is 100.99 USD to 198.86 USD: the price is 17.6% below the high and 62.2% above the low.

Its market capitalisation is 10.47B USD.

Repligen reports return on equity of 2.3%, an operating margin of 8.1% and revenue up 10.9% year over year.

It holds more cash than debt, a net cash position of 170.74M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 203.21 USD is 24.1% above the current price. The next earnings report is expected on 23 February 2027.